4th Mar 2005 17:37
Skyepharma PLC04 March 2005 For Immediate Release 4 March 2005 SkyePharma PLC PAXIL CR CLARIFICATION LONDON, UK, 4 March 2005 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) notes theannouncement today by GlaxoSmithKline ("GSK") concerning the halting of the USdistribution of Paxil CR, a treatment for depression and several anxietydisorders. GSK stated that the halt in distribution results from manufacturingissues which do not pose a health risk to patients. The FDA is advising thatpatients taking Paxil CR should continue taking their tablets and talk withtheir healthcare provider if they have questions. GSK is working with the FDA toresolve these issues as quickly as possible. SkyePharma provided the formulation of Paxil CR, but has no involvement in itsmanufacturing. About SkyePharma PLC SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now ten approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. For further information please contact:SkyePharma PLC +44 207 491 1777Michael Ashton, Chief Executive OfficerPeter Laing, Director of Corporate Communications +44 207 491 5124Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Rebecca Skye Dietrich This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.LGlaxosmithkline